Indian Institute of Technology (Indian School of Mines), Dhanbad, India.
AarogyaAI Innovations Private Limited, Bengaluru, India.
J Biomol Struct Dyn. 2024;42(20):10937-10949. doi: 10.1080/07391102.2023.2259486. Epub 2023 Sep 20.
Clinical resistance against bedaquiline (BDQ) remains intractable to anti-tuberculosis therapies since its introduction to the market over a decade ago. Herein, we investigated the structural and mechanical aspects of BDQ resistance in AtpE, MmpR5, and PepQ. The known target-specific resistant single non-synonymous mutations were refined to high-grade candidates. Thus, 7 (AtpE), 5 (MmpR5), and 1 (PepQ) single nucleotide polymorphisms (SNPs) and one insertion frameshift mutation in MmpR5 were recreated at the molecular level, and these phenotypic models were then directed to stringent dynamics to define time-scaled changes. The AtpE variants destabilized the structure; mainly, L59V, E61D, and I66M were detrimental to the complex fitness, while L74V and L114P boosted the BDQ binding to MmpR5. The first three and last two alterations gave rise to loss- and gain-of-function to AtpE and MmpR5, respectively. Hence, these five mutants are functionally relevant and therapeutically targetable hotspots of BDQ resistance. There were no noticeable changes in PepQ data analysis. The present study revealed that MmpR5 mutations confer BDQ resistance, whereas AtpE and PepQ SNPs display low susceptibility. These results were tallied with the published findings, which testified to the pursued method's reliability and accuracy. We hope these data and inferences could be helpful for the futuristic design of novel TB drugs.Communicated by Ramaswamy H. Sarma.
自十多年前贝达喹啉(BDQ)上市以来,其临床耐药性一直是抗结核治疗的难题。在此,我们研究了 AtpE、MmpR5 和 PepQ 中 BDQ 耐药性的结构和力学方面。对已知的靶标特异性耐药性单非同义突变进行了细化,以确定高等级候选突变。因此,在分子水平上重建了 7(AtpE)、5(MmpR5)和 1(PepQ)个单核苷酸多态性(SNP)和 MmpR5 中的一个插入移码突变,并将这些表型模型引导至严格的动力学中,以定义随时间变化的变化。AtpE 变体使结构不稳定;主要是 L59V、E61D 和 I66M 对复合物适应性有害,而 L74V 和 L114P 则增强了 BDQ 与 MmpR5 的结合。前三个和后两个变化分别导致 AtpE 和 MmpR5 的功能丧失和获得功能。因此,这五个突变体是具有功能相关性的,是 BDQ 耐药性的治疗靶点。PepQ 数据的分析没有明显变化。本研究表明,MmpR5 突变赋予 BDQ 耐药性,而 AtpE 和 PepQ SNP 显示出低敏感性。这些结果与已发表的研究结果一致,证明了所采用方法的可靠性和准确性。我们希望这些数据和推论能够为新型结核病药物的未来设计提供帮助。由 Ramaswamy H. Sarma 交流。